Novartis Pharmaceuticals UK Limited Sustainability Profile
Novartis Pharmaceuticals UK Limited, a prominent player in the global healthcare landscape, is headquartered in Great Britain. Established in 1996, the company has made significant strides in the pharmaceutical industry, focusing on innovative medicines and advanced therapies across various therapeutic areas, including oncology, cardiology, and immunology. With a commitment to research and development, Novartis is renowned for its unique portfolio of prescription medications and cutting-edge treatments that address unmet medical needs. The company has achieved notable milestones, including the launch of groundbreaking therapies that have transformed patient care. As a leader in the pharmaceutical sector, Novartis Pharmaceuticals UK Limited continues to enhance its market position through strategic partnerships and a robust pipeline of products, solidifying its reputation for excellence in healthcare innovation.
DitchCarbon Score
How does Novartis Pharmaceuticals UK Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Pharmaceuticals UK Limited's score of 60 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis Pharmaceuticals UK Limited's reported carbon emissions
In 2023, Novartis Pharmaceuticals UK Limited reported total carbon emissions of approximately 4,710,409,000 kg CO2e. This figure includes 245,725,000 kg CO2e from Scope 1 emissions, 44,102,000 kg CO2e from Scope 2 emissions, and a significant 4,420,582,000 kg CO2e from Scope 3 emissions. This represents a decrease from 2022, when total emissions were about 5,237,736,000 kg CO2e, with Scope 1 at 258,757,000 kg CO2e, Scope 2 at 106,579,000 kg CO2e, and Scope 3 at 4,829,157,000 kg CO2e. Novartis Pharmaceuticals UK Limited is a current subsidiary of Novartis AG, and its emissions data is cascaded from the parent company. The company has not specified any reduction targets or initiatives in its climate commitments, indicating a potential area for future development. The absence of defined targets suggests that while the company is actively monitoring its emissions, it may need to establish clearer goals to align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 343,149,000 |
| Scope 2 | 147,501,000 |
| Scope 3 | 7,663,118,000 |
How Carbon Intensive is Novartis Pharmaceuticals UK Limited's Industry?
How Carbon Intensive is Novartis Pharmaceuticals UK Limited's Location?
Novartis Pharmaceuticals UK Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Pharmaceuticals UK Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
